Similar improvement in lung function, dyspnea, exercise capacity with lung volume reduction surgery, bronchoscopic lung volume reduction
HealthDay operates under the strictest editorial standards. Our syndicated news content is completely independent of any financial interests, is based solely on industry-respected sources and the latest scientific research, and is carefully fact-checked by a team of industry experts to ensure accuracy.
- All articles are edited and checked for factual accuracy by our Editorial Team prior to being published.
- Unless otherwise noted, all articles focusing on new research are based on studies published in peer-reviewed journals or issued from independent and respected medical associations, academic groups and governmental organizations.
- Each article includes a link or reference to the original source.
- Any known potential conflicts of interest associated with a study or source are made clear to the reader.
Please see our Editorial and Fact-Checking Policy for more detail.Editorial and Fact-Checking Policy
HealthDay Editorial Commitment
HeathDay is committed to maintaining the highest possible levels of impartial editorial standards in the content that we present on our website. All of our articles are chosen independent of any financial interests. Editors and writers make all efforts to clarify any financial ties behind the studies on which we report.
FRIDAY, Sept. 23, 2022 (HealthDay News) -- For patients with emphysema, lung volume reduction surgery (LVRS) and bronchoscopic lung volume reduction (BLVR) lead to similar improvements in lung function, dyspnea, and exercise capacity, according to a study presented at the European Respiratory Society International Congress 2022, held from Sept. 4 to 6 in Barcelona, Spain.
Sara Buttery, from the National Heart and Lung Institute at Imperial College London, and colleagues randomly assigned 88 patients with emphysema to receive LVRS or BLVR (41 and 47 patients, respectively). Outcomes were assessed at one year with the iBODE score, which was a composite disease severity measure, including body mass index, airflow obstruction, dyspnea, and exercise capacity.
The researchers found that both groups improved to a similar extent at 12-month follow-up, with no difference observed between the treatment groups in the i-BODE composite score (LVRS, −1.10; BLVR, −0.82) or any of its individual components. Similar reductions in gas trapping were produced by both treatments (−36.1 and −30.5, respectively). No difference was seen between the treatment groups in terms of survival, with one death in each arm.
"The results of this study will be important for clinicians and patients in guiding decision-making around which treatment option to choose when a person is suitable for either approach, providing more evidence around expected outcomes and risks," Buttery said in a statement.
This story may be outdated. We suggest some alternatives.
The content contained in this article is over two years old. As such our recommendation is that you reference the articles below for the latest updates on this topic. This article has been left on our site as a matter of historic record. Please contact us at email@example.com with any questions.
Published on September 23, 2022
Read this Next
Other Trending Articles